Low platelet counts (thrombocytopenia) lead to bleeding. Using adenovirus as a vector in gene transfer experiments consistently led to low platelet counts, according to a 2007 study. (Hat tip to Tetyana Obukhanyk). The first sentence in its abstract reads,
“Thrombocytopenia has been consistently reported following the administration of adenoviral gene transfer vectors.”
Update April 15: “Most of these patients are developing antibody against what’s called platelet factor 4, which causes platelets to clump together,” said Dr. Greg Poland, director of the Mayo Clinic’s Vaccine Research Group in Rochester, Minnesota.
“We also know that adenoviruses themselves can cause platelet activation and binding,” said Poland, who is also a consultant for multiple Covid-19 vaccine manufacturers, including Johnson & Johnson.
If the experts knew this–and it seems they certainly did–why wasn’t the FDA and its advisory committee informed before the vaccine was authorized?
In 2021, Norway appears to have independently verified this. It seems Norway is not part of the EU, and its pharmacovigilance is apparently not farmed out to the Eupean Medicines Agency, which has become a creature of Pharma. Norway found not only low platelets after administering adenovirus vaccine, but an extraordinary incidence of obvious bleeding episodes. One should conclude that there will also be other types of bleeding episodes, especially (unnoticed) gastrointestinal bleeding, which have not yet been identified.
From the Norwegians:
“The findings show that vector vaccines more often lead to skin bleeding, nose bleeds or bleeding from gums than the mRNA vaccines,” says doctor and researcher Lill Trogstad of the Norwegian Institute of Public Health (FHI).
In a new study, researchers compared the incidence of bleeding after the first dose of vaccination in people receiving vector vaccines and mRNA vaccines. In vector vaccine, 2.8 percent of vaccinated people experienced bleeding. The corresponding figures for those receiving an MRNA vaccine were 0.1. The probability of experiencing bleeding episodes was 20 times higher in subjects vaccinated with vector vaccine compared to mRNA vaccine.
–The figures may mean that the vector vaccine not only leads to severe cases of blood clots and low plate numbers as we have seen in rare cases, but also can lead to minor bleeding episodes in a greater proportion of those vaccinated. We need further studies to understand possible mechanisms behind it,” says Trogstad.
The study has not yet been published in the journal, that is, it is so-called preprint.
Higher incidence of bleeding among women
More women than men reported bleeding. 3.1 per cent of women who received a vector vaccine reported skin bleeding compared to 1.3 per cent of men. That makes up 115 out of 3,752 women and 9 out of 685 men. The increased incidence among women is in line with what has been seen among patients hospitalized with blood clots and low platelet counts at hospitals in Norway and Germany.
The researchers found no increased incidence of bleeding in the risk groups. There was also no difference between age groups. However, the study population was relatively young, so a thorough analysis of the impact of age was not carried out.
Background and method
In Norway and Germany, there have been several very serious cases of blood clots and low platelet counts in people who have received vector vaccine against covid-19. The researchers therefore assumed that a larger group of subjects vaccinated with a vector vaccine could have experienced less severe bleeding reactions.
They asked participants in the ongoing if they had experienced side effects, including bleeding from the skin, nose and gums, after covid-19 vaccination. The researchers then compared the incidence of bleeding between the groups that had received vector vaccine and mRNA vaccine.
66 643 participants responded to the survey. 11 per cent reported receiving a vaccine against covid-19. 2874 reported being vaccinated with an mRNA vaccine and 4437 with the vector vaccine from AstraZeneca.